BioNTech SE
HealthcareNASDAQ:BNTX · NASDAQ Global Select
+$1.00 today
Vol 1.13M · Avg 0.99M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$2.8B of revenue converted into -$1.3B of net income for the selected period. Gross margin is 40.3% and net margin is -158.5%, showing how much revenue survives after costs and taxes. EPS is $-5.09, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.8B +0.2% | $2.8B -28.0% | $3.8B -77.9% | $17.3B -8.8% | $19.0B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $616.5M +13.9% | $541.3M -9.8% | $599.8M -80.0% | $3.0B +2.9% | $2.9B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $2.1B -3.2% | $2.2B -31.4% | $3.2B -77.5% | $14.3B -10.9% | $16.1B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 77.6% -2.7pp | 80.3% -4.0pp | 84.3% +1.6pp | 82.7% -2.0pp | 84.7% | 9.8% | 28.9% | 38.3% |
| Research & Development | $2.0B -10.3% | $2.3B +26.4% | $1.8B +16.0% | $1.5B +61.9% | $949.2M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $698.2M +16.6% | $599.0M +7.4% | $557.7M +3.0% | $541.2M +65.4% | $327.2M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $2.8B -21.6% | $3.5B +39.4% | $2.5B +51.2% | $1.7B +114.1% | $781.4M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $367.7M +23.4% | $298.0M +62.5% | $183.4M +48.7% | $123.3M +64.0% | $75.2M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$628.0M -71.1% | -$367.1M -126.7% | $1.4B -89.5% | $13.1B -12.7% | $15.0B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -22.8% -9.4pp | -13.3% -49.4pp | 36.1% -39.6pp | 75.7% -3.4pp | 79.1% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$623.9M +52.5% | -$1.3B -290.4% | $690.4M -94.5% | $12.6B -17.3% | $15.3B | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -22.6% +25.1pp | -47.8% -65.9pp | 18.1% -55.0pp | 73.0% -7.5pp | 80.5% | 16.6% | 24.1% | 22.0% |
| Interest Income | $252.2M | $0 -100.0% | $351.3M +641.7% | $47.4M +2929.2% | $1.6M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $13.6M +3.6% | $13.2M +69.6% | $7.8M -50.9% | $15.8M +181.1% | $5.6M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$385.5M -160.6% | $636.6M +28.4% | $495.7M +59.2% | $311.4M +231.2% | -$237.4M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$1.0B -48.9% | -$677.7M -157.1% | $1.2B -90.8% | $13.0B -13.9% | $15.0B | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -36.6% -12.0pp | -24.6% -55.7pp | 31.1% -43.8pp | 74.8% -4.5pp | 79.3% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $81.9M +760.8% | -$12.4M -104.8% | $255.8M -92.7% | $3.5B -26.0% | $4.8B | $1.3B | -$1.6B | $745.2M |
| Net Income | -$1.1B -64.0% | -$665.3M -171.5% | $930.3M -90.1% | $9.4B -8.3% | $10.3B | $4.9B | $4.8B | $4.7B |
| Net Margin | -39.6% -15.4pp | -24.2% -48.5pp | 24.4% -30.1pp | 54.5% +0.3pp | 54.2% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$5 -62.8% | -$3 -171.6% | $4 -89.8% | $38 -13.2% | $44 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$5 -62.8% | -$3 -172.3% | $4 -89.7% | $37 -10.0% | $41 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $241.7M +0.5% | $240.4M -0.1% | $240.6M -1.1% | $243.3M -0.3% | $244.0M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $241.7M +0.5% | $240.4M -0.9% | $242.7M -2.8% | $249.8M -3.8% | $259.7M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Teva Pharmaceutical Industries Limited
NYSE:TEVA
$40.32B
Natera, Inc.
NASDAQ:NTRA
$30.37B
Biogen Inc.
NASDAQ:BIIB
$29.53B
DexCom, Inc.
NASDAQ:DXCM
$29.08B
Koninklijke Philips N.V.
NYSE:PHG
$25.70B
Royalty Pharma plc
NASDAQ:RPRX
$23.60B
United Therapeutics Corporation
NASDAQ:UTHR
$23.17B
Incyte Corporation
NASDAQ:INCY
$21.68B
STERIS plc
NYSE:STE
$20.26B
Genmab A/S
NASDAQ:GMAB
$15.40B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does BNTX generate?
BioNTech SE (BNTX) reported $2.76B of revenue in fiscal 2025.
Is BNTX profitable?
BioNTech SE (BNTX) reported -$1,091,261,192.00 of net income, with a net margin of -39.6%.
Explore More
Continue the stock analysis
Jump to another research area for this company.